How have VBIV shares performed in 2024?

VBI Vaccines' stock was trading at $0.5875 at the beginning of the year. Since then, VBIV shares have increased by 7.9% and is now trading at $0.6337. View the best growth stocks for 2024 here .

When is VBI Vaccines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our VBIV earnings forecast .

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) released its earnings results on Monday, March, 13th. The biopharmaceutical company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.40) by $0.20. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analyst estimates of $1.98 million. VBI Vaccines had a negative net margin of 1,403.15% and a negative trailing twelve-month return on equity of 199.61%.

When did VBI Vaccines' stock split?

VBI Vaccines shares reverse split on the morning of Wednesday, April 12th 2023. The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets () , Stifel Nicolaus () , Wunderlich () , Standpoint Research () , Duncan Williams () , Soleil Securities () , Sterne Agee CRT () , Robert W. Baird () , Wellington Shields () and Macquarie () .

How do I buy shares of VBI Vaccines?

Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VBIV

VBI Vaccines (VBIV) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free VBIV Stock Alerts

$0.63

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.61
▼
$0.65
50-Day Range: $0.56
▼
$0.92
52-Week Range: $0.45
▼
$3.53

Volume: 163,515 shs
Average Volume: 1.09 million shs
Market Capitalization: $18.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get VBI Vaccines alerts:

VBI Vaccines MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.30% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: -0.32
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.39) to ($0.51) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.25 out of 5 stars

Medical Sector

816th out of 912 stocks

Pharmaceutical Preparations Industry

376th out of 420 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for VBI Vaccines.

4.0

Short Interest

Percentage of Shares Shorted
1.30% of the float of VBI Vaccines has been sold short.
Short Interest Ratio / Days to Cover
VBI Vaccines has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in VBI Vaccines has recently decreased by 4.56%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
VBI Vaccines does not currently pay a dividend.
Dividend Growth
VBI Vaccines does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
VBI Vaccines has received a 51.81% net impact score from Upright. VBI Vaccines seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for VBI Vaccines is -0.75.

1.5

News and Social Media Coverage

News Sentiment
VBI Vaccines has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for VBI Vaccines this week, compared to 1 article on an average week.
Search Interest
12 people have searched for VBIV on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added VBI Vaccines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VBI Vaccines insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.35% of the stock of VBI Vaccines is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 12.26% of the stock of VBI Vaccines is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for VBI Vaccines are expected to grow in the coming year, from ($1.39) to ($0.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VBI Vaccines is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VBI Vaccines is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
VBI Vaccines has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About VBI Vaccines Stock (NASDAQ:VBIV)

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

VBIV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VBIV Stock News Headlines

April 18, 2024 | americanbankingnews.com

VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.com

April 16, 2024 | businesswire.com

VBI Vaccines Reports Full Year 2023 Financial Results

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 11, 2024 | businesswire.com

VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 11, 2024 | investing.com

VBI Vaccines secures $2 million in direct offering

April 11, 2024 | americanbankingnews.com

Head-To-Head Survey: VBI Vaccines (NASDAQ:VBIV) and Summit Therapeutics (NASDAQ:SMMT)

April 10, 2024 | americanbankingnews.com

VBI Vaccines (NASDAQ:VBIV) Coverage Initiated by Analysts at StockNews.com

April 9, 2024 | businesswire.com

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 3, 2024 | businesswire.com

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

April 2, 2024 | msn.com

VBI Vaccines expands collaboration with Canadian government

April 2, 2024 | businesswire.com

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

March 31, 2024 | finance.yahoo.com

VBI Vaccines Inc. (VBIV)

March 22, 2024 | finance.yahoo.com

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

February 15, 2024 | bizjournals.com

North Carolina biotech inks $30M deal to expand its global pipeline

February 14, 2024 | msn.com

VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences

February 14, 2024 | finance.yahoo.com

Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines

February 14, 2024 | benzinga.com

Why Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

February 14, 2024 | finance.yahoo.com

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

February 14, 2024 | businesswire.com

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

February 13, 2024 | markets.businessinsider.com

Brii Biosciences To Buy VBI's IP Rights In BRII-179

February 13, 2024 | prnewswire.com

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

February 7, 2024 | msn.com

VBI Vaccines Secures Forbearance Agreement Extensions

November 20, 2023 | finance.yahoo.com

VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

November 14, 2023 | msn.com

VBI Vaccines Non-GAAP EPS of -$0.38, revenue of $6.62M misses by $6.63M

November 14, 2023 | finance.yahoo.com

VBI Vaccines Reports Third Quarter 2023 Financial Results

October 26, 2023 | finance.yahoo.com

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

See More Headlines

Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2023
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VBIV
CUSIP: N/A
CIK: 764195
Web: www.vbivaccines.com
Phone: (617) 830-3031
Fax: N/A
Employees: 190
Year Founded: 2001

Profitability

EPS (Most Recent Fiscal Year): ($11.6824)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,300,000.00
Net Margins: -1,403.15%
Pretax Margin: -1,403.15%
Return on Equity: -199.61%
Return on Assets: -58.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.65
Quick Ratio: 0.55

Sales & Book Value

Annual Sales: $8.68 million
Price / Sales: 2.08
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.46 per share
Price / Book: 0.08

Miscellaneous

Outstanding Shares: 28,430,000
Free Float: 25,489,000
Market Cap: $18.02 million
Optionable: Optionable
Beta: 1.93

Social Links

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Jeffery R. Baxter FCMA (Age 63)
President, CEO & Director
Comp: $908.06k
Dr. David Evander Anderson (Age 54)
Chief Scientific Officer
Comp: $534.25k
Dr. Francisco Diaz-Mitoma FRCPC (Age 69)
M.D., Ph.D., Chief Medical Officer
Comp: $544.52k
Ms. Nell Beattie (Age 36)
CFO, Head of Corporate Development & Director
Nicole Anderson
Director of Corporate Communications & Investor Relations
Ms. Athena Kartsaklis (Age 59)
Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer
Mr. Avi Mazaltov (Age 62)
Global Head of Manufacturing & GM of SciVac
Mr. Misha Nossov
Senior VP of Global Commercial Supply Strategy & Head of Europe
Mr. T. Adam Buckley (Age 48)
Senior Vice President of Business Development
Mr. John Robert Dillman (Age 56)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VBIV Stock Analysis - Frequently Asked Questions

How have VBIV shares performed in 2024?: VBI Vaccines' stock was trading at $0.5875 at the beginning of the year. Since then, VBIV shares have increased by 7.9% and is now trading at $0.6337.
View the best growth stocks for 2024 here.
When is VBI Vaccines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our VBIV earnings forecast.
How were VBI Vaccines' earnings last quarter?: VBI Vaccines Inc. (NASDAQ:VBIV) released its earnings results on Monday, March, 13th. The biopharmaceutical company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.40) by $0.20. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analyst estimates of $1.98 million. VBI Vaccines had a negative net margin of 1,403.15% and a negative trailing twelve-month return on equity of 199.61%.
When did VBI Vaccines' stock split?: VBI Vaccines shares reverse split on the morning of Wednesday, April 12th 2023. The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of VBI Vaccines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().
How do I buy shares of VBI Vaccines?: Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VBIV) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial